🇺🇸 FDA
Patent

US 10081811

Organic compositions to treat Beta-ENaC-related diseases

granted A61KA61K31/713A61P

Quick answer

US patent 10081811 (Organic compositions to treat Beta-ENaC-related diseases) held by Arrowhead Pharmaceuticals, Inc. expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Sep 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/713, A61P, A61P1/00, A61P1/18